All Releases
 |
Emisphere Technologies Announces Extension of Maturity Date for Convertible Promissory Note
Feb 24, 2010
|
15.8 KB |
|
| |
CEDAR KNOLLS, N.J., Feb 24, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company
that focuses on a unique and improved delivery of pharmaceutical
compounds and nutritional supplements using its Eligen(R)
Technology, today announced that Novartis Pharma AG has agreed to
furt...
|
|
Emisphere to Present at 12th Annual BIO CEO & Investor Conference
Feb 2, 2010
|
17.1 KB |
|
| |
CEDAR KNOLLS, N.J., Feb 02, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company
that focuses on a unique and improved delivery of therapeutic molecules
using its Eligen(R) Technology, today announced that President
and Chief Executive Officer, Michael V. Novinski, will present at ...
|
|
Novo Nordisk Starts Phase I Trial with Long-Acting Oral GLP-1 Analogue
Jan 13, 2010
|
20.5 KB |
|
| |
CEDAR KNOLLS, N.J., Jan 13, 2010 (BUSINESS WIRE) -- Emisphere Technologies, Inc. today announced that Novo Nordisk has
initiated its first Phase I clinical trial with a long-acting oral GLP-1
analogue (NN9924). This milestone releases a $2 million payment to
Emisphere, whose proprietary Eligen(R) Technology is used in
...
|
|
Meta-Analysis of Independent Research Supports Potential for Oral Salmon Calcitonin Using Emisphere's Eligen(R) Technology as Therapeutic Option for Persistent Musculoskeletal Pain
Dec 21, 2009
|
18.1 KB |
|
| |
CEDAR KNOLLS, N.J., Dec 21, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced a
meta-analysis published in the December 2009 edition of Rheumatology
Reports examining independent evidence of the analgesic action of
the hormone calcitonin. This publication restates the potential of
ca...
|
|
Emisphere Technologies Reports DMC Recommendation to Proceed with Phase 3 Clinical Trials with Oral Calcitonin for Osteoporosis and Osteoarthritis
Dec 10, 2009
|
15.3 KB |
|
| |
CEDAR KNOLLS, N.J., Dec 10, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that an
independent Data Monitoring Committee ("DMC") informed Novartis and its
partner Nordic Bioscience about their recommendation to proceed with the
Osteoporosis ("OP") Phase 3 Study 2303 and the Osteoarthritis ...
|
|
Emisphere Technologies Announces Extension of Maturity Date for Novartis Convertible Promissory Note
Nov 30, 2009
|
15.8 KB |
|
| |
CEDAR KNOLLS, N.J., Nov 30, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company
that focuses on a unique and improved delivery of pharmaceutical
compounds and nutritional supplements using its Eligen(R)
Technology, today announced that Novartis Pharma AG has agreed to extend
...
|
|
Emisphere Technologies to Present at the New York Society of Security Analysts' 13th Annual Biotech & Specialty Pharma Investment Conference
Nov 24, 2009
|
15.7 KB |
|
| |
CEDAR KNOLLS, N.J., Nov 24, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company
that focuses on a unique and improved delivery of therapeutic molecules
and pharmaceutical compounds using its Eligen(R) Technology,
today announced that President and Chief Executive Officer, Michael ...
|
|
Emisphere Technologies Announces Financial and Operational Results for the Third Quarter and First Nine Months of 2009
Nov 9, 2009
|
31.1 KB |
|
| |
CEDAR KNOLLS, N.J., Nov 09, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced financial
and operational results for the third quarter and nine months ended
September 30, 2009.
THIRD QUARTER FINANCIAL RESULTSFor the three months ended September 30, 2009, Emisphere reported a net
loss of $4.0...
|
|
Emisphere Technologies Appoints Tim Rothwell to the Board of Directors
Nov 5, 2009
|
17.0 KB |
|
| |
CEDAR KNOLLS, N.J., Nov 05, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that Tim
Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to
the Company's Board of Directors effective immediately. Mr. Rothwell's
appointment fills the vacancy created by Franklin Berger, who r...
|
|
Emisphere Technologies Announces Third Quarter 2009 Conference Call
Nov 4, 2009
|
16.9 KB |
|
| |
CEDAR KNOLLS, N.J., Nov 04, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that
management will host a conference call to discuss the Company's
financial and operational results for the third quarter ended September
30, 2009 on Monday, November 9, 2009 at 10:00 AM EST. A press release
...
|
|
Interim Study Data Demonstrate Eligen(R) B12 Oral Formulation Achieves Comparable Results to B12 Injection
Nov 2, 2009
|
18.4 KB |
|
| |
CEDAR KNOLLS, N.J., Nov 02, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that interim
data from an ongoing study demonstrated its high-dose oral Eligen(R)
B12 (1000mcg) performed as well as or better than B12 injections in
individuals with Vitamin B12 deficiency. Normal levels of serum B...
|
|
Study Results: Novel Oral PTH Formulation Using Emisphere's Eligen(R) Technology Showed Potential Therapeutical Advantages to Available Injectable PTH in Postmenopausal Osteoporotic Women
Oct 20, 2009
|
18.4 KB |
|
| |
CEDAR KNOLLS, N.J., Oct 20, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB:EMIS) today announced study results
demonstrating that a single dose of the novel oral parathyroid hormone
PTH1-34, which utilizes Emisphere's proprietary Eligen(R) Drug
Delivery Technology and absorption-enhancer carrier molecule 5-CNAC...
|
|
Study Results Suggest Oral Salmon Calcitonin Using Eligen(R) Drug Delivery Technology May Reduce Cartilage and Bone Degradation in Osteoarthritis
Oct 15, 2009
|
20.9 KB |
|
| |
CEDAR KNOLLS, N.J., Oct 15, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTCBB: EMIS) announced study results in
which twice-daily oral salmon calcitonin using Emisphere's proprietary
Eligen(R) Drug Delivery Technology significantly suppressed
markers of cartilage and bone degradation versus placebo in men and
...
|
|
Emisphere Technologies Introduces First Commercially Available Product, Oral Eligen(R) B12
Oct 8, 2009
|
19.2 KB |
|
| |
CEDAR KNOLLS, N.J., Oct 08, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that the
Company is introducing and launching its first commercially available
product, oral Eligen(R) B12 (100 mcg). Oral Eligen(R)
B12 (100 mcg) has been specifically developed to help improve Vitamin
B12...
|
|
Emisphere Technologies Announces Publication in Clinical Pharmacology and Therapeutics of Encouraging Data from an Independent Clinical Study of an Oral Eligen-GLP-1 Formulation on Glucose Homeostasis
Sep 8, 2009
|
17.8 KB |
|
| |
CEDAR KNOLLS, N.J., Sep 08, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced the
publication of an article in the September issue of Clinical
Pharmacology and Therapeutics, that describes previously reported
findings of an independent clinical study designed to assess the
pharmacoki...
|
|
Emisphere Technologies to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Sep 1, 2009
|
16.7 KB |
|
| |
CEDAR KNOLLS, N.J., Sep 01, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company
that focuses on a unique and improved delivery of therapeutic molecules
and pharmaceutical compounds using its Eligen(R) Technology,
today announced that President and Chief Executive Officer, Michael ...
|
|
Emisphere Technologies Announces Closing of $4 Million Registered Direct Offering and $4 Million Private Placement
Aug 21, 2009
|
18.6 KB |
|
| |
CEDAR KNOLLS, N.J., Aug 21, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced the
completion of its previously announced sale of 5,714,286 shares of its
common stock and warrants to purchase up to 2,685,714 additional shares
of common stock in a registered direct offering with two institutio...
|
|
Emisphere Technologies to Raise $4 Million in Registered Direct Offering and Additional $4 Million in Private Placement
Aug 19, 2009
|
17.8 KB |
|
| |
CEDAR KNOLLS, N.J., Aug 19, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that it has
received commitments from two institutional investors to purchase $4
million of securities in a registered direct offering. Emisphere entered
into a securities purchase agreement with these investors pu...
|
|
Emisphere Technologies Announces Financial and Operational Results for the Second Quarter and First Six Months of 2009
Aug 11, 2009
|
28.0 KB |
|
| |
CEDAR KNOLLS, N.J., Aug 11, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) today announced financial
and operational results for the second quarter and six months ended June
30, 2009.
SECOND QUARTER FINANCIAL RESULTSFor the three months ended June 30, 2009, Emisphere reported a net loss
of $3.7 million,...
|
|
Emisphere Technologies Announces Second Quarter 2009 Conference Call
Aug 7, 2009
|
16.6 KB |
|
| |
CEDAR KNOLLS, N.J., Aug 07, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTC BB: EMIS) announced today that
management will host a conference call to discuss the Company's
financial and operational results for the second quarter ended June 30,
2009 on Tuesday, August 11, 2009 at 10:00 AM EDT. A press release will
...
|
|
|
